Tanespimycin (17-AAG) Liposomes, Formulation XT28.1

PEGylated liposomes containing Hsp90 inhibitor Tanespimycin (17-AAG). Tanespimycin exhibits 100-fold higher binding affinity to HSP90 derived from tumor cells vs normal cells, and induces apoptosis, necrosis, autophagy, and mitophagy. Tanespimycin is insoluble in aqueous media. This product is a pre-formulated liposomal version of Tanespimycin which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.